The Global Medullary Thyroid Cancer Drugs Market is driven by increasing prevalence of thyroid cancer
Medullary thyroid cancer (MTC) is a rare form of thyroid cancer that develops from the parafollicular C cells of the thyroid gland. MTC accounts for about 5% of all thyroid cancers. Drugs for MTC include cabozantinib (Cabometyx), vandetanib (Caprelsa) and lenvatinib (Lenvima). These drugs help slow or stop the growth of cancer cells and alleviate related symptoms.
The medullary thyroid cancer drugs market is estimated to be valued at USD 156 Mn in 2024 and is expected to reach USD 315 Mn by 2031, growing at a compound annual growth rate (CAGR) of 10.6% from 2024 to 2031.
Key Takeaways
Key players operating in the Medullary Thyroid Cancer Drugs market are Exelixis Inc., Bristol-Myers Squibb Company and Eisai Co. Ltd.
The growing incidence of Medullary Thyroid Cancer Drugs Market across the world is boosting the demand for effective drugs to treat the condition. According to statistics, globally around 1500-1800 new cases of MTC are reported annually. With increasing awareness, early diagnosis and availability of targeted drugs, the number of patients opting for treatment has risen substantially over the past few years.
Get more insights on: Medullary Thyroid Cancer Drugs Market
English
Français
Español
Português
Deutsch
Türkçe
Dutch
Italiano
Russian
Romaian